Lilly 'insider advantage in M&A' reads like template litigation until a named transaction appears - but the market still trades the smear
The Opportunity
This is a governance/headline-risk motif: allegations of insider advantage around M&A can pressure a high-multiple mega-cap because they create a "what else" question even when the claim is thin. The direction is SHORT because governance smear narratives tend to be asymmetric in the short term: you do not need hard proof for the stock to pay a risk premium if the story catches and repeats.
The Timing
Freshness is low (45) and the upstream due diligence explicitly says it could not locate a named transaction tied to the allegation, which is why you should treat this as fragile until specificity arrives. In a Mixed 58 regime with high crosswinds, trading a low-specificity governance headline is inherently choppy. Confirmation would be a named deal plus a filed complaint or a proxy/disclosure dispute with dates; contradiction is the allegation remaining generic template language that never attaches to a real event.
The Evidence
7A carries the negative mechanism but also flags the key weakness: absence of a named transaction and weak hydration. That makes this a low-quality but potentially tradable narrative risk signal, and the system keeps conviction at 52 while capping trade confidence at 47.